ClinicalTrials.gg
RecruitingNCT04973540IRISUpdated Nov 19, 2021

A Clinical Trial to Evaluate the Safety and Efficacy of IBS Angel in Patients With Pulmonary Artery Stenosis

An interventional study of Iron Bioresorbable Scaffold System (IBS Angel) in Pulmonary Artery Stenosis, sponsored by Biotyx Medical (Shenzhen) Co., Ltd.. Recruiting at 10 sites in China. Open to participants aged 1 Year to 14 Years. Per ClinicalTrials.gov, last updated 2021-11-19.

Sponsored by Biotyx Medical (Shenzhen) Co., Ltd. (part of LifeTech Scientific Corporation) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
1 Year to 14 Years
Sex
All
01

Study summary

This is a prospective, multi-center, single-arm clinical trial to evaluate the safety and efficacy of Iron Bioresorbable Scaffold System (IBS Angel) in patients with pulmonary artery stenosis.

Read the detailed description

82 patients with pulmonary artery stenosis will be treated with the Iron Bioresorbable Scaffold System (IBS Angel) developed by Biotyx Medical (Shenzhen) Co., Ltd. This study is designed as a prospective, multi-center, single-arm clinical trial. Enrolled patients will undergo IBS Angel implantation and will be followed up at 1, 3, 6, 12, and 24 months post-procedure.

02

Conditions studied

  • Pulmonary Artery Stenosis
03

In context

Lead sponsor

Biotyx Medical (Shenzhen) Co., Ltd. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must between 1 and 14 years old.
  2. Patients who have congenital or secondary pulmonary artery stenosis (including pulmonary artery trunk, left pulmonary artery and right pulmonary artery), and meeting one of the following criteria:

    A: The pressure gradient across the stenosis ≥20mmHg measured by catheter; B: The degree of pulmonary artery stenosis ≥50% ( calculated by (diameter of adjacent normal segments - residual lumen diameter of the stenosis segment)/diameter of adjacent normal segments ×100%); C: The ratio of right ventricular systolic pressure to aortic systolic pressure ≥50%.

  3. Patients and whose family have high compliance, voluntarily participate in and sign the form, and complete the 2-year follow-up.
  4. Patients have >2 year after successful stent implantation.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have a history of disease related to iron overload or iron disorder, such as hereditary hemochromatosis, etc.
  2. Patients with cardiopulmonary function that cannot tolerate surgery, such as severe heart failure ( Grade III and above) that cannot be controlled by active medical treatment.
  3. Patients with known allergy to contrast agent, iron and its degradation products.
  4. Patients with hemorrhagic disorders.
  5. Patients with on antiplatelet agents and anticoagulant therapy.
  6. Patients with thrombosis at the vascular wall of target lesion or the distal or proximal location.
  7. Patients with known severe renal or hepatic insufficiency which are unsuitable for index procedure as per investigator judgement.
  8. Previous stent implantation has been performed to treat the target lesion;
  9. Patients with severe stenosis or excessive tortuosity in the targeted vessels, or anatomical abnormalities, making it difficult for device to reach the target lesion.
  10. Other conditions that are not suitable for stent delivery or balloon expansion.
  11. Patient who have already participated in another drug or medical device clinical trial that have not yet completed or withdrawn within 3 months before the screening period of this trial.
  12. Patients who are not suitable for participating the trial as per investigator judgement.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    IBS Angel

    Iron Bioresorbable Scaffold System

    Device: Iron Bioresorbable Scaffold System (IBS Angel)

Interventions

  • DeviceIron Bioresorbable Scaffold System (IBS Angel)

    Subjects in this arm will be implanted with IBS Angel.

06

What researchers measure

Primary outcomes

  1. Rate of freedom from in-stent restenosis

    Defined on a per target lesion basis.

    Time frame: 12 months

  2. Rate of procedural success

    Defined on a per target lesion basis.

    Time frame: Immediately post-procedure

Secondary outcomes

  1. Rate of technical success

    Defined on a per target lesion basis.

    Time frame: Immediately post-procedure

  2. Rate of freedom from in-stent restenosis

    Defined on a per target lesion basis.

    Time frame: 1 month

  3. Rate of freedom from in-stent restenosis

    Defined on a per target lesion basis.

    Time frame: 3 months

  4. Rate of freedom from in-stent restenosis

    Defined on a per target lesion basis.

    Time frame: 6 months

  5. Rate of device-related adverse events

    Time frame: 1 month

  6. Rate of device-related serious adverse events

    Time frame: 1 month

  7. Rate of device-related adverse events

    Time frame: 3 months

  8. Rate of device-related serious adverse events

    Time frame: 3 months

  9. Rate of device-related adverse events

    Time frame: 6 months

  10. Rate of device-related serious adverse events

    Time frame: 6 months

  11. Rate of device-related adverse events

    Time frame: 12 months

  12. Rate of device-related serious adverse events

    Time frame: 12 months

  13. Rate of device-related adverse events

    Time frame: 24 months

  14. Rate of device-related serious adverse events

    Time frame: 24 months

  15. Rate of unplanned surgery or re-intervention

    Time frame: 1 month

  16. Rate of unplanned surgery or re-intervention

    Time frame: 3 months

  17. Rate of unplanned surgery or re-intervention

    Time frame: 6 months

  18. Rate of unplanned surgery or re-intervention

    Time frame: 12 months

  19. Rate of unplanned surgery or re-intervention

    Time frame: 24 months

  20. Rate of stent thrombosis

    Time frame: 1 month

  21. Rate of stent thrombosis

    Time frame: 3 months

  22. Rate of stent thrombosis

    Time frame: 6 months

  23. Rate of stent thrombosis

    Time frame: 12 months

  24. Rate of stent thrombosis

    Time frame: 24 months

  25. Rate of all-cause death

    Time frame: 1 month

  26. Rate of all-cause death

    Time frame: 3 months

  27. Rate of all-cause death

    Time frame: 6 months

  28. Rate of all-cause death

    Time frame: 12 months

  29. Rate of all-cause death

    Time frame: 24 months

  30. Rate of stent displacement

    Time frame: 1 month

  31. Rate of stent displacement

    Time frame: 3 months

  32. Rate of stent displacement

    Time frame: 6 months

  33. Rate of stent displacement

    Time frame: 12 months

  34. Rate of adverse events

    Time frame: 1 month

  35. Rate of serious adverse events

    Time frame: 1 month

  36. Rate of adverse events

    Time frame: 3 months

  37. Rate of serious adverse events

    Time frame: 3 months

  38. Rate of adverse events

    Time frame: 6 months

  39. Rate of serious adverse events

    Time frame: 6 months

  40. Rate of adverse events

    Time frame: 12 months

  41. Rate of serious adverse events

    Time frame: 12 months

  42. Rate of adverse events

    Time frame: 24 months

  43. Rate of serious adverse events

    Time frame: 24 months

  44. Rate of device deficiency

    Time frame: Day 0

07

Study locations

2 of 10 sites recruiting
  • The Second Xiangya Hospital of Central South University
    Changsha, China
    Not yet recruiting
    • Zhenfei Fang · Principal investigator
  • Children's Hospital of Chongqing Medical University
    Chongqing, China
    Not yet recruiting
    • Qijian Yi · Principal investigator
  • The People's Hospital of Gaozhou
    Gaozhou, China
    Recruiting
    • Lian Hu · Principal investigator
  • Guangdong Provincial People's Hospital
    Guangzhou, China
    Recruiting
    • Zhiwei Zhang · Principal investigator
  • Fuwai Yunnan Cardiovascular Hospital
    Kunming, China
    Not yet recruiting
    • Gejun Zhang · Principal investigator
  • Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, China
    Not yet recruiting
    • Fen Li · Principal investigator
  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, China
    Not yet recruiting
    • Sun Chen · Principal investigator
  • General Hospital of Northern Theater Command of Chinese People's Liberation Army
    Shenyang, China
    Not yet recruiting
    • Qiguang Wang · Principal investigator
  • Shenzhen Children's Hospital
    Shenzhen, China
    Not yet recruiting
    • Boning Li · Principal investigator
  • Fuwai Central China Cardiovascular Hospital
    Zhengzhou, China
    Not yet recruiting
    • Taibing Fan · Principal investigator
08

References and documents

Publications

  • Sun L, Li JJ, Xu YK, Xie YM, Wang SS, Zhang ZW. Initial status and 3-month results relating to the use of biodegradable nitride iron stents in children and the evaluation of right ventricular function. Front Cardiovasc Med. 2022 Aug 1;9:914370. doi: 10.3389/fcvm.2022.914370. eCollection 2022. PubMed 35979021 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2021 (actual). Primary completion is estimated for Jul 2024, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2021
First posted
Jul 22, 2021
StartActual
Jul 13, 2021
Primary completionEst.
Jul 2024
CompletionEst.
Dec 2025
Last update
Nov 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04973540
Responsible party
Sponsor
First posted
Jul 22, 2021
Start date
Jul 13, 2021
Primary completion
Jul 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
Nov 19, 2021

Study contacts

Ying Xia
Contact
xiaying@lifetechmed.com
86 13760184511

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion